Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STP705 in Hypertrophic Scar
NCT02956317Phase 2Completed
- Sponsor
- Sirnaomics
- Start
- Jan 2017
- Primary completion
- Jan 2018
- Modality
- Nanoparticles, Conjugated siRNA, Chemically Modified siRNA
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Hypertrophic Scar (HS) comparing STP705 with Placebo (2 arms). Primary endpoint: Patient and Observer Scar Assessment Scale at 32 weeks. Started Jan 2017; status: completed.
02
Drugs
sirna-tgf-b1 + sirna-cox-2
03
Conditions
Hypertrophic Scar (HS)
Beyond the preview
Go deeper on NCT02956317.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02956317.